Notably, combining Bcl9@TP with anti-PD-1 therapy led to a more pronounced suppression of proliferative activity, with an approximate 70% reduction in Ki-67 positivity, consistent with the observed tumor growth inhibition (Figure 4F). This evidence concerns the gene BCL9 and neoplasm.